Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is currently developing RVX-208, which is a first-in-class small molecule for treating atherosclerosis and the first BET bromodomain inhibitor in clinical trials. New compounds resulting from Resverlogix’s epigenetic drug discovery, which function by inhibiting BET bromodomains, have the potential to impact multiple diseases, including cancer and autoimmune and neurodegenerative disorders. For more information, visit the company’s Web site at www.resverlogix.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: